TABLE 2 

Characteristics of DENV-specific FL-binding human MAbs

Type of infectionSubject
no.
MAbIgG
subclassa
λ or κa50% neutralization concentration
(EC50, μg/ml), against indicated
dengue virus (D) serotypeb
Fold enhancement of
infection, for indicated
serotype at 1 µg/mlc
D1D2D3D4D1D2D3D4
Primary DENV1
vaccine
491M12.21κ>>>>88301
Primary DENV1
wild type
1061M6.21κ>8>>43291
2J211κ>>>>187281
2I233>>>>5111
101M41κ0.560.275261561
Primary DENV2
wild type
195M221λ795>11114211
Primary DENV3
wild type
31I171λ1088>712277
2A151κ77510106165
1181M71κ0.550.300.020.501111
Secondary
wild type
92C71λ4146225524
10891N51κ0.10.20.50.45297
33871F12.21κ>>>>98117
1C191κ0.060.030.043185168
1153H42λ1134
1841E41λ>>>>89177
1B191λ1236753211
1C181κ0.2>>>91655
1H201κ>>>>4121
1I161λ>>>>5423
1K161κ>>>>716113
1L41κ>>>>131694
1L61λ27166316
1N81λ548611529
2M111κ234420123611
3B41λ22126424
3D181λ>>>>33498
3G51λ>>>>91574
4E81λ0.40.23>713144
5C81κ12135546
5K171κ236521173318
  • a Immunoglobulin isotype, subtype, and light chain utilization were determined by ELISA.

  • b The concentration (µg/ml) at which 50% of virus was neutralized (EC50) is shown for each dengue virus serotype: EC50 values between 1.0 and 10.0 µg/ml are shown, 50% neutralization values of <1.0 µg/ml are shown in bold; EC50 values of <0.1 μg/ml are shown in bold italic. The “>” symbol indicates no neutralization detected when tested at a concentration as high as 10 µg/ml.

  • c Enhancement assays were performed for each antibody at a concentration of 1 µg/ml, separately against each DENV serotype, and results are shown as fold enhancement. Enhancement values greater than 20-fold are shown in bold.